January 6, 2023
Axios recently published an article where Associate Professor of Markets, Public Policy, and Law, Rena Conti discusses the prescription drug approvals expected in 2023, and the already-contentious debates around affordability and equity.
Despite their success in treating conditions like Alzheimer’s or sickle cell disease, the high prices of these drugs cause dilemmas for insurers, governments, and patients. Conti elaborates on this debate by stating, “they will create choices that need to be made and they will also create potential burdens, particularly on the most vulnerable, on people who are the least well-insured and people who live in states or happen to have insurance coverage that is the least generous.”
New discussions about how to pay for some drugs may result from the upcoming drug approvals.
- Do People Believe Generative AI?
- [Fortune] The CFO of the Future
- Would you buy a car from this man?
- [Vox] When You Can’t Speak to the Manager – or Anyone
- [NBC Boston] ‘Ready to Play’: What Boston Officials are Saying About LEGO’s Big Move
- Money: It’s created. It’s destroyed. But what is it?
- Blockchain, Beyond Crypto: An Expert Panel Discussion
- [New York Times] A Dilemma For Governments: How to Pay for Million-Dollar Therapies
- [Fortune] Tesla, JPMorgan, Meta: How Companies That Rely Too Much on One Leader Put Their Operations At Risk
- Heroes from Above But Not (Always) from Within? Gig workers’ reactions to the sudden public moralization of their work